Benefits
CD38 Inhibition / NAD+ Preservation (Theoretical)
CD38 enzyme degrades NAD+ — apigenin inhibits CD38 in vitro and in animal models, theoretically preserving NAD+ levels. Component of longevity protocols seeking to maintain age-related NAD+ decline. Clinical translation in humans not definitively established.
Anxiolytic / Calming Effects
Apigenin binds GABA-A benzodiazepine receptor with modest affinity — basis for chamomile's traditional calming use. trial of chamomile (containing apigenin) showed modest anxiolytic benefit in generalized anxiety disorder vs placebo.
Sleep Support
Chamomile traditionally used for sleep; apigenin contributes via GABA-A receptor activity and circadian effects. Modest sleep onset latency reduction in some trials. Zick et al. 2011 chamomile trial found modest, largely non-significant effects on sleep in adults.
Anti-Inflammatory / Antioxidant
Inhibits NF-κB, COX-2, iNOS in vitro — broad anti-inflammatory profile. Free radical scavenging activity. Component of multi-mechanism cardiovascular and longevity supplementation.
Cancer Chemoprevention Research
Extensive in vitro evidence for apoptosis induction in cancer cell lines (breast, prostate, colon, lung); animal models show tumor growth inhibition. Human clinical translation limited; not established cancer therapy.
Mechanism of action
CD38 Inhibition (NAD+ Pathway)
CD38 is the major NAD+-degrading enzyme; CD38 expression increases with age, contributing to NAD+ decline. Apigenin inhibits CD38 in vitro and animal studies — theoretical NAD+ preservation. Mechanism makes apigenin popular in NMN/NR/longevity stacks. Note: in vitro CD38 IC50 is in micromolar range; achievable plasma levels with oral supplementation are typically nanomolar — clinical CD38 inhibition uncertain.
GABA-A Benzodiazepine Receptor Modulation
Apigenin is a ligand at the benzodiazepine site of the GABA-A receptor — mild positive allosteric modulator. Lower potency than pharmaceutical benzodiazepines but contributes to anxiolytic/calming effects. Basis for chamomile's traditional calming use.
Aromatase Inhibition
Apigenin modestly inhibits aromatase enzyme (CYP19) — the enzyme that converts androgens to estrogens. Theoretical implications for hormone-sensitive conditions; clinical relevance modest at typical supplemental doses.
NF-κB and Inflammatory Pathway Inhibition
Modulates NF-κB signaling, reduces COX-2 and iNOS expression. Broad anti-inflammatory profile basis for chronic inflammation contexts.
Clinical trials
Clinical trial of standardized chamomile extract vs placebo in patients with mild-to-moderate generalized anxiety disorder for 8 weeks.
57 patients with GAD.
Chamomile extract significantly reduced anxiety scores (Hamilton Anxiety Rating Scale) vs placebo. Effect modest. Apigenin contributes to but is not solely responsible for chamomile's effects.
Multiple preclinical studies of apigenin's CD38 inhibition and NAD+ preservation effects in cell culture and animal models.
Cell culture and rodent models.
Apigenin inhibits CD38 in vitro and increases NAD+ in tissues of treated animals. Translates to improved metabolic markers. Human clinical trials testing CD38 inhibition / NAD+ preservation with apigenin specifically are limited — popularized largely from preclinical mechanism plus longevity protocols.